Low-molecular-weight heparin in the treatment of deep venous thrombosis.
Traditionally, acute deep venous thrombosis (DVT) is treated with intravenous heparin followed by oral anticoagulants. With the advent of the low-molecular-weight heparins (LMWHs), this strategy is changing dramatically. LMWHs are compounds derived from standard unfractionated heparin that offer distinct clinical advantages over unfractionated heparin, including better bioavailability, longer half-life, and a more predictable anticoagulant response that obviates the need for laboratory monitoring. The common side effects of unfractionated heparin, including bleeding, thrombocytopenia, and osteoporosis, may be less common with LMWH. For the treatment of established venous thromboembolism, LMWH is at least as safe and effective as unfractionated heparin. Recent studies demonstrate that home therapy of DVT with LMWH, compared with inpatient therapy with unfractionated heparin, produces comparable clinical outcomes and patient satisfaction, with dramatic cost savings. With careful patient selection, home therapy of venous thromboembolism is quickly becoming the new standard of care.
Hauer
K E
KE
Division of General Internal Medicine, School of Medicine, University of California, San Francisco, USA.
D000925:Anticoagulants / Q000494:pharmacology / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D020246:Venous Thrombosis / Q000188:drug therapy*
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight